[Three cases of fatal thrombocytopenia after oxaliplatin-based chemotherapy].
Oxaliplatin is a platinum salt that is particularly effective for treating gastrointestinal tumors. However, some reports state that oxaliplatin-based chemotherapy triggers fatal thrombocytopenia. Myelosuppression is recognized as the main cause of oxaliplatin-related thrombocytopenia, and other mechanisms for this side effect have been suggested, including splenic sequestration of platelets related to oxaliplatin-induced liver damage and immune thrombocytopenia. Other causes of thrombocytopenia such as thrombotic thrombocytopenic purpura, immune thrombocytopenic purpura, heparin-induced thrombocytopenia, and pseudothrombocytopenia should also be considered. We encountered 3 patients who developed fatal thrombocytopenia after oxaliplatin-based chemotherapy and describe the differential diagnosis of fatal thrombocytopenia here.
Division of Gastrointestinal oncology, Cancer Institute Hospital.
Hiroki
H
Osumi
Eiji
E
Shinozaki
Yosuke
Y
Kumekawa
Mariko
M
Ogura
Masato
M
Ozaka
Mitsukuni
M
Suenaga
Satoshi
S
Matsusaka
Keisho
K
Chin
Nobuyuki
N
Mizunuma
Masahiro
M
Yokoyama
D000328:Adult; D000970:Antineoplastic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008875:Middle Aged; D009944:Organoplatinum Compounds / Q000009:adverse effects* / Q000627:therapeutic use; D000077150:Oxaliplatin; D013921:Thrombocytopenia / Q000139:chemically induced*
D000970:Antineoplastic Agents; D009944:Organoplatinum Compounds; D000077150:Oxaliplatin